Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation-Positive Non-Small Cell Lung Cancer.

K, Isomoto; K, Haratani; H, Hayashi; S, Shimizu; S, Tomida; T, Niwa; T, Yokoyama; Y, Fukuda; Y, Chiba; R, Kato; J, Tanizaki; K, Tanaka; M, Takeda; T, Ogura; T, Ishida; A, Ito; K, Nakagawa

doi:10.1158/1078-0432.ccr-19-2027

Public

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation-Positive Non-Small Cell Lung Cancer.

Shared by NobleBlocks on Jan 14, 2020 • 12:00 AM UTC

Authors:

Isomoto K

Haratani K

Hayashi H

Abstract

<h4>Purpose</h4>The impact of EGFR tyrosine kinase inhibitors (TKI) on the tumor immune microenvironment (TME) in non-small cell lung cancer (NSCLC) is unclear.<h4>Experimental design</h4>We retrospectively identified 138 patients with <i>EGFR</i>-mutated NSCLC who underwent rebiopsy after progressi...

Discussions